| Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy L Apetoh, F Ghiringhelli, A Tesniere, M Obeid, C Ortiz, A Criollo, G Mignot, ... Nature medicine 13 (9), 1050-1059, 2007 | 3366 | 2007 |
| Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation M Robson, SA Im, E Senkus, B Xu, SM Domchek, N Masuda, S Delaloge, ... New England Journal of Medicine 377 (6), 523-533, 2017 | 3007 | 2017 |
| 70-gene signature as an aid to treatment decisions in early-stage breast cancer F Cardoso, LJ van’t Veer, J Bogaerts, L Slaets, G Viale, S Delaloge, ... New England Journal of Medicine 375 (8), 717-729, 2016 | 1879 | 2016 |
| Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy A Sistigu, T Yamazaki, E Vacchelli, K Chaba, DP Enot, J Adam, I Vitale, ... Nature medicine 20 (11), 1301-1309, 2014 | 1044 | 2014 |
| The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy L Apetoh, F Ghiringhelli, A Tesniere, A Criollo, C Ortiz, R Lidereau, ... Immunological reviews 220 (1), 47-59, 2007 | 690 | 2007 |
| OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2 … ME Robson, N Tung, P Conte, SA Im, E Senkus, B Xu, N Masuda, ... Annals of Oncology 30 (4), 558-566, 2019 | 674 | 2019 |
| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ... The lancet oncology 18 (12), 1688-1700, 2017 | 649 | 2017 |
| Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 … A Chan, S Delaloge, FA Holmes, B Moy, H Iwata, VJ Harvey, NJ Robert, ... The Lancet Oncology 17 (3), 367-377, 2016 | 641 | 2016 |
| Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study MV Dieci, C Criscitiello, A Goubar, G Viale, P Conte, V Guarneri, G Ficarra, ... Annals of oncology 25 (3), 611-618, 2014 | 540 | 2014 |
| Breast cancer with synchronous metastases: trends in survival during a 14-year period F Andre, K Slimane, T Bachelot, A Dunant, M Namer, A Barrelier, ... Journal of Clinical Oncology 22 (16), 3302-3308, 2004 | 527 | 2004 |
| Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 HJ Burstein, G Curigliano, B Thürlimann, WP Weber, P Poortmans, ... Annals of oncology 32 (10), 1216-1235, 2021 | 524 | 2021 |
| 21-gene assay to inform chemotherapy benefit in node-positive breast cancer K Kalinsky, WE Barlow, JR Gralow, F Meric-Bernstam, KS Albain, ... New England Journal of Medicine 385 (25), 2336-2347, 2021 | 490 | 2021 |
| Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with≥ 2 HER2-directed regimens: phase III NALA trial C Saura, M Oliveira, YH Feng, MS Dai, SW Chen, SA Hurvitz, SB Kim, ... Journal of Clinical Oncology 38 (27), 3138, 2020 | 469 | 2020 |
| Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally … D Miles, J Gligorov, F André, D Cameron, A Schneeweiss, C Barrios, B Xu, ... Annals of Oncology 32 (8), 994-1004, 2021 | 454 | 2021 |
| Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized … JY Pierga, FC Bidard, C Mathiot, E Brain, S Delaloge, S Giachetti, ... Clinical Cancer Research 14 (21), 7004-7010, 2008 | 448 | 2008 |
| Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1 E Vacchelli, Y Ma, EE Baracco, A Sistigu, DP Enot, F Pietrocola, H Yang, ... Science 350 (6263), 972-978, 2015 | 438 | 2015 |
| The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer F Cardoso, S Loibl, O Pagani, A Graziottin, P Panizza, L Martincich, ... European journal of cancer 48 (18), 3355-3377, 2012 | 387 | 2012 |
| Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array F Andre, B Job, P Dessen, A Tordai, S Michiels, C Liedtke, C Richon, ... Clinical cancer research 15 (2), 441-451, 2009 | 367 | 2009 |
| Dual-energy contrast-enhanced digital mammography: initial clinical results C Dromain, F Thibault, S Muller, F Rimareix, S Delaloge, A Tardivon, ... European radiology 21, 565-574, 2011 | 365 | 2011 |
| Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer R Rouzier, L Pusztai, S Delaloge, AM Gonzalez-Angulo, F Andre, ... Journal of Clinical Oncology 23 (33), 8331-8339, 2005 | 328 | 2005 |
